Epratuzumab for Systemic Lupus Erythematosus

被引：22
作者：
Wallace, D. J. [1 ]
Goldenberg, D. M. [2 ,3 ]
机构：
[1] Univ Calif Los Angeles, Cedars Sinai David Geffen Sch Med, Los Angeles, CA USA
[2] Ctr Mol Med & Immunol, Morris Plains, NJ USA
[3] Immunomedics Inc, Morris Plains, NJ USA
来源：
LUPUS | 2013年 / 22卷 / 04期
关键词：
B cells; BILAG; CD22; epratuzumab; immunotherapy; systemic lupus erythematosus; HUMANIZED ANTI-CD22 ANTIBODY; B-CELLS; MONOCLONAL-ANTIBODY; CD22; RECEPTOR; THERAPY; ANTIGEN; EXPRESSION;
D O I：
10.1177/0961203312469692
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Epratuzumab (EMab, UCB, Immunomedics) is a humanized monoclonal antibody targeting CD22 that is being studied in clinical trials for patients with a variety of rheumatic and hematologic conditions, including systemic lupus erythematosus (SLE). An overview of its mechanism of action is followed by a summary of completed lupus studies, and a preview of studies in progress. The agent clearly has anti-inflammatory activity and is a potentially useful agent in the management of autoimmune disorders. Lupus (2013) 22, 400-405.
引用
收藏
页码：400 / 405
页数：6
相关论文
共 34 条
[1]   Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results [J].
Aletaha, D. ;
Strand, V. ;
Smolen, J. S. ;
Ward, M. M. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (02) :238-243
[2]  
Carnahan J, 2003, CLIN CANCER RES, V9, p3982S
[3]   Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab [J].
Carnahan, Josette ;
Stein, Rhona ;
Qu, Zhengxing ;
Hess, Kristen ;
Cesano, Alessandra ;
Hansen, Hans J. ;
Goldenberg, David M. .
MOLECULAR IMMUNOLOGY, 2007, 44 (06) :1331-1341
[4]  
CHAOUCHI N, 1995, J IMMUNOL, V154, P3096
[5]   Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus [J].
Daridon, Capucine ;
Blassfeld, Daniela ;
Reiter, Karin ;
Mei, Henrik E. ;
Giesecke, Claudia ;
Goldenberg, David M. ;
Hansen, Arne ;
Hostmann, Arwed ;
Froelich, Daniela ;
Doerner, Thomas .
ARTHRITIS RESEARCH & THERAPY, 2010, 12 (06)
[6]   Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus [J].
Doerner, Thomas ;
Kaufmann, Joerg ;
Wegener, William A. ;
Teoh, Nick ;
Goldenberg, David M. ;
Burmester, Gerd R. .
ARTHRITIS RESEARCH & THERAPY, 2006, 8 (03)
[7]   CD22 and Autoimmune Disease [J].
Doerner, Thomas ;
Shock, Anthony ;
Smith, Kenneth G. C. .
INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2012, 31 (05) :363-378
[8]   B cells in autoimmunity [J].
Doerner, Thomas ;
Jacobi, Annett M. ;
Lipsky, Peter E. .
ARTHRITIS RESEARCH & THERAPY, 2009, 11 (05)
[9]   A ROLE IN B-CELL ACTIVATION FOR CD22 AND THE PROTEIN-TYROSINE-PHOSPHATASE SHP [J].
DOODY, GM ;
JUSTEMENT, LB ;
DELIBRIAS, CC ;
MATTHEWS, RJ ;
LIN, JJ ;
THOMAS, ML ;
FEARON, DT .
SCIENCE, 1995, 269 (5221) :242-244
[10]  
DORKEN B, 1986, J IMMUNOL, V136, P4470
1234